Drug resistance stands as a primary clinical hurdle in the effective management of MDS/AML patients, often arising during treatment with DAC, a prototypical DNMT inhibitor, consequently resulting in treatment failure [22, 23]. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.